Profile
Tsvetelina Pencheva Hoang formerly worked at Bellicum Pharmaceuticals, Inc., as Director-Translational Research from 2015 to 2018, The Phi Beta Kappa Society, as Member, and Marker Therapeutics, Inc., as Vice President-Research & Development from 2018 to 2024.
Dr. Hoang received her doctorate degree from The Johns Hopkins University and undergraduate degree and graduate degree from Yale University.
Former positions of Tsvetelina Hoang
| Companies | Position | End |
|---|---|---|
| MARKER THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2024-07-31 |
| BELLICUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2018-06-30 |
The Phi Beta Kappa Society
The Phi Beta Kappa Society Miscellaneous Commercial ServicesCommercial Services Operates as a organisation for liberal arts and science education | Corporate Officer/Principal | - |
Training of Tsvetelina Hoang
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Marker Therapeutics, Inc.
Marker Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes cell based immune therapeutics and vaccines for cancer treatment | Health Technology |
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel cellular immunotherapies for various forms of cancer | Health Technology |
The Johns Hopkins University
The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Phi Beta Kappa Society
The Phi Beta Kappa Society Miscellaneous Commercial ServicesCommercial Services Operates as a organisation for liberal arts and science education | Commercial Services |
- Stock Market
- Insiders
- Tsvetelina Hoang
















